Thu, Aug 21, 2014, 10:16 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • atpl1959 atpl1959 Nov 11, 2013 11:43 AM Flag

    Both of the

    Non Hodgkin ADC collaborations with genentech in heavily pretreated relapsed refractory patients appear to be producing a decent amount of Complete remissions in that patient population ranging from 20 -40%( with Rituxan). As both ADC's seem to be targeting the same diseases using different antigen targets, I wonder if getting no response from one potentially allows the patient to be a candidate for the other ADC.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • That is a good question. I believe that patients are pre-screened for cd expression.
      This is more than excellent news for SGEN. Adcetris + Rituxan represents a third drug targeting the same disease. The Roche testing is giving us a window into how well the SGEN trial may do. B cell is about 6bil market for Rituxan. SGEN may have a part of that entire market. While it may not be as lucrative as Rituxan, at the current price point B -cell represents an absolutely huge potential boost in future revenue.
      This is only my worthless opinion.

 
SGEN
42.50-0.49(-1.14%)Aug 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.